{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:01:43Z","timestamp":1787893303250,"version":"build-2784847793"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:p>Background: Recently gene therapy with onasemnogene abeparvovec has been approved for the treatment of spinal muscular atrophy (SMA). As the experience from clinical trials is limited, there are still uncertainties for which patient population the treatment can be considered safe and effective. Methods: We report our experience with eight consecutive patients with SMA who were treated with the standard dose of onasemnogene abeparvovec (1.1\u00d71014 vg\/kg) at the University Hospital Bonn, Germany. All patients received prophylactic immunosuppression with 1 mg\/kg\/d prednisolone for four weeks starting on the day before gene therapy. Results: We treated eight patients (4 male, 4 female, age range 10\u201337 months) with a body weight between 7.1 and 11.9\u200akg. All patients had 2 or 3 copies of the SMN2-gene and were previously treated with nusinersen. Following treatment with onasemnogene abeparvovec all patients showed a temporary increase of the body temperature and an increase of transaminase levels. In all but one patient it was necessary to increase or prolong the standard steroid dose to control the immune response. In one severe case, liver damage was associated with impaired liver function. This patient received a steroid pulse therapy for five days. Blood counts revealed asymptomatic thrombocytopenia (&lt;150\u00d7109\/L) in 6\/8 patients and a significant increase of monocytes following gene therapy. Liver values and blood counts returned to almost normal levels during the post-treatment observation period. Troponin I increased above normal limit in 4\/8 patients but was not associated with any abnormalities on cardiac evaluation. Conclusions: In a broader spectrum of patients, treatment with onasemnogene abeparvovec was associated with a higher rate of adverse events. In our cases it was possible to control the immune response by close monitoring and adaptation of the immunosuppressive regimen. Further research is needed to better understand the immune response following gene therapy and ideally to identify patients at risk for a more severe reaction.<\/jats:p>","DOI":"10.3233\/jnd-200593","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T18:39:39Z","timestamp":1609871979000},"page":"209-216","source":"Crossref","is-referenced-by-count":63,"title":["Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec \u2013A Single Centre Experience"],"prefix":"10.1177","volume":"8","author":[{"given":"Johannes","family":"Friese","sequence":"first","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Geitmann","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Holzwarth","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sassen","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Baur","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Adler","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JND-200593_ref1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.3233\/JND-200593_ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1 Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.3233\/JND-200593_ref3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.3233\/JND-200593_ref4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.3233\/JND-200593_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"18","key":"10.3233\/JND-200593_ref6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.3233\/JND-200593_ref7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.3233\/JND-200593_ref8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.3233\/JND-200593_ref9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","article-title":"[Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101: Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)]","volume":"91","author":"Ziegler","year":"2020","journal-title":"Nervenarzt"},{"issue":"3","key":"10.3233\/JND-200593_ref10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"10.3233\/JND-200593_ref11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"10","key":"10.3233\/JND-200593_ref12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"10.3233\/JND-200593_ref13","doi-asserted-by":"crossref","unstructured":"Waldrop MA , Karingada C , Storey MA , Powers B , Iammarino MA , Miller NF , et al. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Pediatrics. 2020;146(3).","DOI":"10.1542\/peds.2020-0729"},{"issue":"15-16","key":"10.3233\/JND-200593_ref15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cMoving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy\u201d by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"13-14","key":"10.3233\/JND-200593_ref16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.3233\/JND-200593_ref17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.3233\/JND-200593_ref18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.117.032003","article-title":"Combining High-Sensitivity Cardiac Troponin I and Cardiac Troponin T in the Early Diagnosis of Acute Myocardial Infarction","volume":"138","author":"van","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.3233\/JND-200593_ref19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00246-019-02199-9","article-title":"Cardiac Troponin T in Healthy Full-Term Infants","volume":"40","author":"Karlen","year":"2019","journal-title":"Pediatr Cardiol"},{"issue":"8","key":"10.3233\/JND-200593_ref20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00246-019-02198-w","article-title":"What is the Significance of Elevated Troponin I in Children and Adolescents? A Diagnostic Approach","volume":"40","author":"Yoldas","year":"2019","journal-title":"Pediatr Cardiol"},{"issue":"22","key":"10.3233\/JND-200593_ref22","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2014.03.027","article-title":"Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases: Implications for the diagnosis of myocardial infarction","volume":"63","author":"Rittoo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.3233\/JND-200593_ref23","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.3233\/JND-200593_ref24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3345\/kjp.2018.61.6.180","article-title":"Clinical and laboratory profiles of hospitalized children with acute respiratory virus infection","volume":"61","author":"Choi","year":"2018","journal-title":"Korean J Pediatr"},{"issue":"8","key":"10.3233\/JND-200593_ref25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-200593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:36Z","timestamp":1777506576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-200593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":23,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-200593","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}